

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Anders Nykjær		
Title:	MODULATION OF ACTIVITY OF NEUROTROPHINS		
Application No.:	10/539,443	Filing Date:	June 20, 2005
Examiner:	MacFarlane, Stacey Nee	Group Art Unit:	1649
Docket No.:	0088562-033US0	Conf. No.:	6823

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant(s) call(s) the documents listed on the enclosed Form PTO-1449 to the Examiner's attention in this patent application.

Copies of the documents listed on the accompanying Form PTO-1449 are enclosed.

Citation of these documents shall not be construed as (1) an admission that the documents are prior art with respect to the invention or inventions claimed in this application, (2) a representation that a search has been made (other than as indicated by any cited document), or (3) an admission that the cited information is, or is considered to be, material to patentability as defined in § 1.56(b).


This information disclosure statement is submitted under 37 C.F.R. § 1.97(c). The fee of \$180.00 has been authorized via EFS to Deposit Account 04-0258. The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account 04-0258.

Attorney Docket No.:0088562-033US0
FILED VIA EFS

Application No.:10/539,443

FILED VIA EFS

Respectfully submitted,

 13 Nov 2002

Dale C. Hunt
Reg. No. 41,857

Date

DAVIS WRIGHT TREMAINE LLP
505 Montgomery Street, Suite 800
San Francisco, California 94111-6533
Telephone: (415) 276-6500
Facsimile: (415) 276-6599
Email: sf-patents@dwt.com